10050 Federal Register / Vol. 62, No. 43 / Wednesday, March 5, 1997 / Notices

G. Mode of Action

Tebuconazole, the active ingredient of

Folicur 3.6 F is a sterol demethylation

inhibitor (DMI) fungicide. It is systemic

and shows activity against powdery

mildew and black rot infecting grapes.

Tebuconazole provides protective

activity by preventing completion of the

infection process by direct inhibition of

sterol synthesis. It is rapidly absorbed

by plants and translocated systemically

in the young growing tissues.

II. Public Record

EPA invites interested persons to

submit comments on this notice of

filing. Comments must bear a

notification indicating the docket

control number PF–705.

A record has been established for this

notice docket under docket control

number PF–705 (including any

comments and data submitted

electronically as described below). A

public version of this record, including

printed, paper versions of electronic

comments, which does not include any

information claimed as CBI, is available

for inspection from 8:30 a.m. to 4 p.m.,

Monday through Friday, excluding legal

holidays. The public record is located in

Room 1132 of the Public Response and

Program Resources Branch, Field

Operations Division (7506C), Office of

Pesticide Programs, Environmental

Protection Agency, Crystal Mall #2,

1921 Jefferson Davis Highway,

Arlington, VA.

Electronic comments can be sent

directly to EPA at:

opp-docket@epamail.epa.gov

Electronic comments must be

submitted as an ASCII file avoiding the

use of special characters and any form

of encryption. The official record for

this notice of filing, as well as the public

version, as described above will be kept

in paper form. Accordingly, EPA will

transfer all comments received

electronically into printed, paper form

as they are received and will place the

paper copies in the official rulemaking

record which will also include all

comments submitted directly in writing.

The official rulemaking record is the

paper record maintained at the address

in ADDRESSES at the beginning of this

document.

List of Subjects

Environmental protection,

Administrative practice and procedure,

Agricultural commodities, Pesticides

and pests, Reporting and recordkeeping.

Dated: February 19, 1997.

Stephen L. Johnson,

Director, Registration Division, Office of

Pesticide Programs.

[FR Doc. 97–5200 Filed 3–4–97; 8:45 am]

BILLING CODE 6560–50–F

[PF–579A; FRL–5587–1]

Novartis; Pesticide Petition Withdrawal

AGENCY: Environmental Protection

Agency (EPA).

ACTION: Notice of withdrawal of

pesticide petition.

SUMMARY: EPA is withdrawing a

pesticide petition from Novartis

(formerly known as Ciba-Geigy

Corporation) for the combined residues

of the insecticide cyromazine, (N

cyclopropyl-1,3,5-triazine-2,4,6-triamine

plus its major metabolite, melamine,

1,3,5-triazine-2,4-6-triamine) for use in

or on certain commodites.

FOR FURTHER INFORMATION CONTACT:

George T. LaRocca, Product Manager

(PM) 13, Registration Division, (7505C),

Office of Pesticide Programs,

Environmental Protection Agency, 401

M. St., SW., Washington, DC 20460.

Office location, telephone number and

e-mail address: Rm. 200, CM#2, 1921

Jefferson Davis Highway, Arlington, VA;

703–305–6100; e-mail:

larocca.george@epamail.epa.gov.

SUPPLEMENTARY INFORMATION: EPA in a

notice issued in the Federal Register of

August 18, 1993 (58 FR 43892),

announced that Novartis, P.O. Box

18300, Greensboro, NC 27419, had filed

a pesticide petition (PP) 6F3422

proposing to amend 40 CFR part

180.414 to establish tolerances for the

combined residues of the insecticide

cyromazine, (N cyclopropyl-1,3,5-

triazine-2,4,6-triamine plus its major

metabolite, melamine, 1,3,5-triazine-2,4-

6-triamine) for use in or on cabbage,

sweet potatoes, sugar beets (roots and

tops), and sorghum (grain, forage and

fodder). The tolerances were to cover

residues resulting from the planting of

these crops as rotational crops following

the harvest of cyromazine treated crops.

On August 26, 1996 Novartis notified

EPA that it requests that the petition be

withdrawn without prejudice to future

filing. The Agency has withdrawn the

subject pesticide petition.

List of Subjects

Environmental protection,

Administrative practice and procedure,

Agricultural Commodities, Pesticides

and pests, Reporting and recordkeeping

requirements.

Dated: February 17, 1997.

Stephen L. Johnson,

Director, Registration Division, Office of

Pesticide Programs.

[FR Doc. 97–4884 Filed 3–4–97; 8:45 am]

BILLING CODE 6560–50–F

[PF–700; FRL–5586–1]

Rhone-Poulenc Ag Company;

Pesticide Tolerance Petition Filing

AGENCY: Environmental Protection

Agency (EPA).

ACTION: Notice of filing.

SUMMARY: This notice announces the

filing of a pesticide petition proposing

to establish tolerances for residues of

thiodicarb and its metabolite in or on

leafy vegetables, broccoli, cabbage and

cauliflower. The notice includes a

summary of the petition prepared by the

petitioner, Rhone-Poulenc Ag Company.

DATES: Comments, identified by the

docket control number [PF–700], must

be received on or before, April 4, 1997.

ADDRESSES: By mail, submit written

comments to: Public Response and

Program Resources Branch, Field

Operations Division (7506C), Office of

Pesticide Programs, Environmental

Protection Agency, 401 M St. SW.,

Washington, DC 20460. In person, bring

comments to: Rm. 1132, Crystal Mall #2,

1921 Jefferson Davis Highway,

Arlington, VA 22202.

Comments and data may also be

submitted electronically by sending

electronic mail (e-mail) to: oppdocket@epamail.epa.gov. Electronic

comments must be submitted either as

an ASCII file avoiding the use of special

characters and any form of encryption.

Comments and data will also be acceped

on disks in Wordperfect in 5.1 file

format or ASCII file format. All

comments and data in electronic form

must be identified by the docket control

number [PF–700]. Electronic comments

on this notice may be filed online at

many Federal Depository Libraries.

Additional information on electronic

submissions can be found below this

document.

Information submitted as a comment

concerning this notice may be claimed

confidential by marking any part or all

of that information as ‘‘Confidential

Business Information’’ (CBI).

Information so marked will not be

disclosed except in accordance with

procedures set forth in 40 CFR Part 2.

No CBI should be submitted through email. A copy of the comment that does

not contain CBI must be submitted for

inclusion in the public record.
Federal Register / Vol. 62, No. 43 / Wednesday, March 5, 1997 / Notices 10051

Information not marked confidential

may be disclosed publicly by EPA

without prior notice.

FOR FURTHER INFORMATION CONTACT:

Dennis H. Edwards, Jr. Product Manager

(PM 19), Registration Division, (7505C),

Office of Pesticide Programs,

Environmental Protection Agency, 401

M St., SW., Washington, DC. Office

location, telephone number and e-mail

address: Rm., 207, Crystal Mall #2, 1921

Jefferson Davis Highway, Arlington,

VA.; Telephone: 703–305–6386, e-mail:

edwards.dennis@epamail.epa.gov.

SUPPLEMENTARY INFORMATION: EPA has

received pesticide petitions (PP) 6F3417

and 7F3516 from Rhone-Poulenc Ag

Company, P.O. Box 12014, 2 T.W.

Alexander Drive, Research Triangle

Park, NC 27709. These petitions

propose, pursuant to section 408(d) of

the Federal Food, Drug and Cosmetic

Act (FFDCA), 21 U.S.C. section 346a, to

amend 40 CFR part 180 by establishing

tolerances for the combined residues of

the insecticide thiodicarb (Dimethyl

N,N-[thiobis[[(methylimino)

carbonyl]oxy]] bis [ethanimidothioate])

and its metabolite methomyl (S-methyl

N [(methylcarbamoyl)oxy]-

thioacetimadate) in or on the following

raw agricultural commodities: leafy

vegetables at 35 parts per million (ppm),

broccoli at 7 ppm, cabbage at 7 ppm,

and cauliflower at 7 ppm. The proposed

analytical method is HPLC.

As required by section 408(d) of the

FFDCA, as recently amended by the

Food Quality Protection Act (FQPA),

Rhone-Poulenc Ag Company included

in the petition a summary of the

petitions and authorization for the

summary to be published in the Federal

Register in a notice of receipt of the

petition. The summary represents the

views of Rhone-Poulenc Ag Company;

EPA is in the process of evaluating the

petition. As required by section

408(d)(3), EPA is including the

summary as a part of this notice of

filing. EPA may have made minor edits

to the summary for the purpose of

clarity.

I. Petition Summary

A. Residue Chemistry

The metabolism of thiodicarb in

plants and animals is adequately

understood. Adequate analytical

methods are available for enforcement

purposes. There are no livestock feed

items associated with this petition; there

are no problems of secondary residues

in meat, milk, poultry or eggs.

B. Toxicological Profile

1. Acute toxicity. EPA evaluation of

the three acute oral toxicity studies in

rats indicated the LD50 in males and

females to be >50 miligrams/kilograms

(mg/kg). Based on the results of these

studies, thiodicarb is placed in Toxicity

Category II. The acute dermal toxicity

study in rabbits resulted in a LD50 of

>2,000 mg/kg for both males and

females. The acute inhalation LC50 was

found to be >0.56 mg/l in male and

female rats. The primary eye irritation

study showed iridal involvement and

moderate to severe conjunctival

irritation. All positive reactions cleared

within 4 days and eyes had returned to

a normal appearance by day 7 following

treatment. There was no irritation in the

primary dermal irritation study.

Thiodicarb was a weak dermal

sensitizer in guinea pigs.

Conclusion. Based on the acute

toxicity data cited above, RhonePoulenc Ag Company concludes that

thiodicarb does not pose any acute

dietary risks.

2. Mutagenicity. Mutagenicity studies

completed include Salmonella

typhimurium mammalian microsome

reverse mutation assay (negative),

Saccharomyces cerevisiae reverse

mutation (negative), mitotic crossing

over (negative) and gene conversion

(positive in strain D7 and negative in

strain D4), primary DNA damage in

Escherichia coli (negative), mouse

lymphoma gene mutation assay

(equivocal positive), chromosomal

aberration assay in CHO cells (negative),

UDS assay with primary rat hepatocytes

(negative), in vivo micronucleus test in

mouse bone marrow (negative) and

dominant lethal test in rats (negative).

Conclusion. Thiodicarb was tested in

a variety of mutagenicity assays and was

negative in all but the mouse lymphoma

assay, in which there was only a weak

to equivocal response and for mitotic

gene conversion in Saccharomyces

cerevisiae. EPA has previously

concluded that overall there is low

concern for the mutagenicity of

thiodicarb.

3. Metabolism. The metabolism of

thiodicarb has been studied in several

animal and plant species and studies

submitted and accepted by EPA. The

metabolism in plants and animals is

adequately understood for the purposes

of this tolerance.

4. Chronic effect. Based on the

available chronic toxicity data, the

Health Effects Division-RfD/Peer Review

Committee of the EPA recommended in

their RfD/Peer Review Report (Ghali,

June 18, 1996) that the Reference Dose

(RfD) for thiodicarb remain unchanged

from the previously established value of

0.03 mg/kg/day. The recently completed

rat studies support the no observed

effect level (NOEL) of 3 mg/kg/day

established in previous studies. An

Uncertainty Factor (UF) of 100 was

applied to account for both the

interspecies extrapolation and

intraspecies variability.

5. Carcinogenicity. The potential

oncogenicity of thiodicarb has been

fully evaluated by the EPA’s Health

Effects Division Carcinogenicity Peer

Review Committee (CPRC) (Taylor and

Rinde, June 10, 1996). The committee

determined that the available database

was adequate for the determination of

the carcinogenicity of thiodicarb in

animals and concluded that thiodicarb

should be classified in Group B2. While

Rhone-Poulenc disagrees with the

classification of thiodicarb and the

interpretation of the study results (as

described below) Rhone-Poulenc agrees

with the risk characterization procedure

recommended by the CPRC and concurs

that the recommended procedures are

fully adequate to protect humans from

dietary exposure to thiodicarb.

The CPRC recommended that a

margin of exposure methodology be

applied for the estimation of human risk

because the findings observed in the

oncogenicity studies occurred only at

the highest doses tested in the studies

and in the case of mice the highest dose

tested may even have been excessive. In

addition, there was no evidence of

genotoxicity.

a. Rhone-Poulenc feels that the results

in the most recent oncogenicity study in

rats should not be considered indicative

of a carcinogenic response in the Leydig

cells of the rats for the following

reasons:

i. Compared to the control groups,

both sexes at the high dose level

displayed fewer tumors and there were

fewer with multiple benign and

malignant tumors.

ii. There was a statistically

significant decrease in pituitary

adenomas in the high dose animals

relative to controls (10 percent vs 56

percent ) indicating more high dose than

control animals had normal pituitaries

at the end of the study. The incidence

of pituitary adenomas is well below the

historical control range (10 percent vs a

range of 43 to 80 percent ). Pituitary

activity is known to be critical in the

regulation of benign Leydig cell tumor

formation through the secretion of

luteinizing hormone. Increased pituitary

activity in aged male rats would be

expected to secondarily result in

increased benign Leydig cell tumor

formation.

iii. There was no statistical increase

in benign interstitial cell tumors relative

to the concurrent controls when all
10052 Federal Register / Vol. 62, No. 43 / Wednesday, March 5, 1997 / Notices

animals were included in the statistical

analysis.

iv. There is clear evidence that

exposure to 900 ppm thiodicarb resulted

in increased survival for male rats

relative to controls. The 2 year survival

rate for high dose males was 1.3 times

that of controls (58 percent vs 45

percent, respectively). Benign

interstitial cell tumors are very common

age related tumors. Because survival

was 1.3 times higher in the high dose

group than in controls, the high dose

animals should be expected to have a

higher raw incidence of common age

related tumors.

v. Benign interstitial cell tumors do

not transform into a more aggressive

form with time.

vi. Benign interstitial cell tumors are

very common in rats and highly

uncommon in humans. There is an

absence of epidemiological evidence

that Leydig cell tumors in rats are

relevant for human health risk

assessment. The Food and Drug

Administration (FDA), and European

regulatory authorities in general do not

consider these findings to be relevant

for human health risk assessment.

Numerous scientific symposia/

discussions have been held regarding

the lack of relevance of rat Leydig cell

changes for human risk assessment.

b. Rhone-Poulenc feels that the results

in the most recent mouse oncogenicity

study should not be considered

indicative of a carcinogenic response in

the liver cells of the mice for the

following reasons:

i. The evidence shows that

thiodicarb is not oncogenic in mice at

doses which do not exceed the

maximum tolerated dose (MTD).

ii. There was no evidence to suggest

liver oncogenicity in the first mouse

study at doses up to 10 mg/kg/day or in

the second study at doses up to 70 mg/

kg/day.

iii. In the second study where there

was evidence suggestive of an oncogenic

response in the liver, the MTD was

significantly exceeded based on

increased mortality in females and a

dramatic body weight gain depression

in the males. The body weight gains for

males at 1,000 mg/kg/day were 54

percent of the control male gains during

the first year of the study. The body

weight gains for the 1,000 mg/kg/day

group females were 85 percent of

controls for the same time period.

Survivability at 97 weeks was also

significantly decreased in males (41

percent versus 58 percent in control

males) and females (24 percent versus

51 percent in control females).

iv. Other evidence that the MTD was

exceeded included severe and sustained

liver toxicity demonstrated by increased

liver weights, hepatocyte hypertrophy,

single cell necrosis and hemosiderin

deposition by 52 weeks and increased

bilirubin and ALT, increased liver

weight, hepatocyte hypertrophy, bile

duct hyperplasia, hepatocyte

pleomorphism and hemosiderin

deposition at 97 weeks of treatment.

Conclusion. The oncogenicity studies

with thiodicarb fully conform to the

currently accepted guidelines for this

study type. Rhone-Poulenc Ag Company

believes that the results of the studies

provide only minimal evidence that the

compound is oncogenic in rodents.

After analysis of the data, EPA scientists

recently determined that a margin of

exposure of 100 applied to the lowest

NOEL from the chronic studies with

thiodicarb would provide adequate

safety for any risks to humans. RhonePoulenc agrees with this risk assessment

approach and is confident that it will

provide adequate safety for all human

population subgroups including infants

and children.

6. Teratology. Several teratology

studies exist on thiodicarb in rats,

rabbits, and mice. These are reviewed

below:

a. A teratology study in rats was

conducted at doses of 0, 0.5, 1.0, 3, and

100 mg/kg/day. No signs of

teratogenicity were observed.

b. A teratology study was conducted

in rats at doses of 0, 1, 10 and 30 mg/

kg/day. No signs of teratogenicity were

observed.

Data from both studies can be (and

were by EPA) used to derive maternal

and developmental NOELs and lowest

observed effect levels (LOELs). Based on

data from both studies, the maternal

NOEL and LOEL were determined to be

10 and 20 mg/kg/day, respectively. The

developmental NOEL and LOEL were

determined to be 3 and 10 mg/kg/day,

respectively, based on delayed

ossification of sternebrae.

c. A teratology study in rabbits was

conducted at doses of 0, 5, 20 and 40

mg/kg/day. No signs of teratogenicity

were observed. The NOEL and LOEL for

maternal toxicity were determined to be

20 and 40 mg/kg/day, respectively. The

developmental NOEL was determined to

be 40 mg/kg/day. As this was the

highest level tested, no LOEL for

developmental toxicity was determined.

d. A teratology study in mice was

conducted at doses of 0, 50, 100 and 200

mg/kg/day. No signs of teratogenicity

were observed. The maternal NOEL and

LOEL were determined to be 100 and

200 mg/kg/day, respectively. As no fetal

effects were observed at all, the

developmental NOEL can be considered

to be 200 mg/kg/day.

Conclusion. Based on all the studies

above, Rhone-Poulenc Ag Company

does not believe that thiodicarb is a

teratogen, or that it presents any

unreasonable risk to children.

7. Reproductive effects. Two

reproduction studies were recently

conducted with thiodicarb; one doserangefinding study and one definitive

study.

a. In the dose-rangefinding study, rats

were administered thiodicarb in their

diets at concentrations of 0, 200, 600,

1,800, and 3,000 ppm. Maternal toxicity,

as evidenced by decreased pup viability

at birth and day 4, was seen at the three

highest doses. Also at the three highest

doses, decreased pup growth occurred.

Therefore, the NOEL for both maternal

and fetal effects was determined to be

200 ppm.

b. In the definitive study, thiodicarb

was administered in the diets of rats at

concentrations of 0, 100, 300, and 900

ppm. Fetal body weight gain at 100 ppm

was significantly decreased when

compared with concurrent controls

resulting in the conclusion that, strictly

speaking, no NOEL was reached for fetal

effects in this study. An independent

expert consulting firm was contracted

with to statistically derive from these

data a conservative NOEL for all effects.

These experts concluded that a

conservative NOEL for all effects would

be 80 ppm, equivalent to an average

daily dose of 5.20 mg/kg/day. EPA

subsequently utilized a Benchmark Dose

approach to estimate the NOEL for this

study, and ultimately concluded that,

based on all the data and all the

different analyses of the data, 100 ppm

is at or near the NOEL for reproductive/

developmental toxicity. It is significant,

too, that this NOEL is higher than the

NOEL from the chronic toxicity/

oncogenicity study in rats, where the

NOEL is used to determine the

Reference Dose for thiodicarb.

Conclusion. Based on the studies

cited above, Rhone-Poulenc Ag

Company believes that thiodicarb does

not pose an unreasonable risk of

reproductive effects to parents or their

offspring. Further, as none of the effects

observed in the cited studies are

classically related to any specific

endocrine mechanism, Rhone-Poulenc

Ag Company believes that thiodicarb is

not an endocrine disrupter.

C. Aggregate Exposure/Cumulative

Effects

The Dietary Analysis for the Proposed

Use of thiodicarb on leafy vegetables has

been run by EPA and summarized in a

document dated June 17, 1991

(Schaible, S.A.). Using the Theoretical
Federal Register / Vol. 62, No. 43 / Wednesday, March 5, 1997 / Notices 10053

Maximum Residue Contributions

(TMRC) calculated from the tolerances

and estimated consumption data for

various populations (very conservative

estimates) a value of 0.019213 is

obtained for the TMRC which represents

64.0 percent of the established reference

dose was reached for the overall U.S.

population. The Dietary Analysis for the

Proposed Use of thiodicarb on broccoli,

cabbage and cauliflower has been run by

EPA and summarized in a document

dated July 9, 1990 (Briggs, R.). Using the

TMRC calculated from the tolerances

and estimated consumption data for

various populations (very conservative

estimates). A value of 0.015225 is

obtained for the TMRC which represents

50.8 percent of the established reference

dose utilized for the overall U.S.

population. None of the population

subgroups exceeded the 100 percent

level of the reference dose. This value

includes all pending and published

tolerances, including apples, tomatoes

and peppers for which Rhone-Poulenc

Ag Company does not currently have a

registration. This is a large

overestimation of the actual dietary

exposure to thiodicarb because it

assumes 100 percent of crops treated

and maximum residue levels present.

The FQPA of 1996 lists three other

potential sources of exposure to the

general population that must be

addressed, these are pesticides in

drinking water, exposure from nonoccupational sources, and the potential

cumulative effect of pesticides with

similar toxicological modes of action.

Based on the available studies of

thiodicarb in the environment which

show a short half-life in soil (1.5 days),

Rhone-Poulenc Ag Company does not

anticipate residues of thiodicarb in

drinking water. There is no established

Maximum Concentration Level or

Health Advisory Level for thiodicarb

under the Safe Drinking Water Act.

The potential for non-occupational

exposure to the general public is also

insignificant. There are no residential

lawn or garden uses for thiodicarb

products where the general population

may be exposed via inhalation or

dermal routes.

Rhone-Poulenc concludes that

consideration of a common mechanism

of toxicity is not appropriate at this time

since there is no reliable data to indicate

that the toxic effects caused by

thiodicarb would be cumulative with

those of any other compound. Based on

this point, Rhone-Poulenc has

considered only the potential risks of

thiodicarb in it’s exposure assessment.

D. Safety Determinations

1. U.S. population in general. Using

the very conservative exposure

estimates described above, the

conclusion reached is that aggregate

exposure to thiodicarb will utilize no

more than 64 percent of the established

reference dose. Rhone-Poulenc Ag

Company has conducted a preliminary

Dietary Risk Exposure Study (DRES)

with TAS, Inc. which utilizes actual

data (where available) for percent crops

treated and residue data from FDA and

Cal-EPA monitoring programs (no

detectable residues of thiodicarb were

observed in these databases, so as a

conservative estimate, all methomyl

residues were assumed to result from

thiodicarb use). Only registered and

conditionally registered uses (including

leafy vegetables, broccoli, cabbage and

cauliflower) were included in the

analysis. The study concluded that

chronic exposure estimates are well

below the endpoints of concern.

Chronic exposure estimates are 0.1

percent of the RfD or less for all

population groups. Based on this study

and the above points, Rhone-Poulenc Ag

Company believes there is a reasonable

certainty that no harm will result from

aggregate exposure to thiodicarb.

2. Infants and children. Referring to

the conclusions and summary in the

Developmental and Reproductive

Toxicity section stated above, RhonePoulenc Ag Company believes there is

no additional sensitivity for infants and

children and that an additional safety

factor for infants and children is not

warranted. The RfD of 0.03 mg/kg/day is

appropriate for assessing aggregate risk

to this subpopulation. For the infant and

children (1 to 6 years of age)

populations only 0.1 percent of the

reference dose was used in the DRES

study discussed above.

Based on the completeness and

reliability of the toxicology data and the

dietary analysis Rhone-Poulenc Ag

Company concludes that there is a

reasonable certainty that no harm will

result to infants and children from

aggregate exposure to thiodicarb

residues.

E. International Tolerances

There are no Codex maximum residue

levels established for thiodicarb on leafy

vegetables, broccoli, cabbage or

cauliflower.

II. Public Record

EPA invites interested persons to

submit comments on this notice of

filing. Comments must bear a

notification indicating the docket

control number [PF–700].

A record has been established for this

notice under docket control number

[PF–700] (including comments and data

submitted electronically as described

below). A public version of this record,

including printed paper versions of

electronic comments, which does not

include any information claimed as CBI,

is available for inspection from 8:30

a.m. to 4 p.m., Monday through Friday,

excluding legal holidays. The public

record is located in Rm. 1132 of the

Public Response and Program Resources

Branch, Field Operations Division

(7506C), Office of Pesticide Programs,

Environmental Protection Agency,

Crystal Mall #2, 1921 Jefferson Davis

Highway, Arlington, VA.

Electronic comments can be sent

directly to EPA at:

opp-docket@epamail.epa.gov

Electronic comments must be

submitted as ASCII file avoiding the use

of special characters and any form of

encryption.

The official record for this notice, as

well as the public version, as described

above will be kept in paper form.

Accordingly, EPA will transfer all

comments received electronically into

printed, paper form as they are received

and will place the paper copies in the

official notice record which will also

include all comments submitted directly

in writing. The official notice record is

the paper record maintained at the

address in ‘‘ADDRESSES’’ at the

beginning of this document.

Authority: 21 U.S.C. 346a.

List of Subjects

Environmental Protection,

Administrative practice and procedure,

Agricultural commodities, Pesticide and

pest, Reporting and recordkeeping

requirements.

Dated: February 10, 1997.

Stephen L. Johnson,

Director, Registration Division, Office of

Pesticide Programs.

[FR Doc. 97–4879 Filed 3–4–97; 8:45 am]

BILLING CODE 6560–50–F

[OPP–181034; FRL 5591–2]

Bifenthrin; Receipt of Application for

Emergency Exemption, Solicitation of

Public Comment

AGENCY: Environmental Protection

Agency (EPA).

ACTION: Notice.

SUMMARY: EPA has received a specific

exemption request from the Washington